Latest Articles
Second New Zealand anticancer “stealth” drug targeted for clinical development
4 August 2011
A second anticancer “stealth” drug designed by New Zealand scientists has been targeted for clinical development under a collaborative agreement between Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).
read more
Compound designed in New Zealand starves cancer cells of glucose
4 August 2011
Scientists from the Auckland Cancer Society Research Centre (ACSRC) and Maurice Wilkins Centre for Molecular Biodiscovery have designed a new compound that starves certain cancer cells of glucose, depriving them of energy.
read more